24.6 C
New York
Sunday, June 14, 2026

Tag: options

newssourceFORcompanyinformationcontent1marketreleases

Academy Sports + Outdoors Celebrates Father’s Day With “Dadmas” Campaign Focused on Fun, Family, and Legendary Value

Company is offering premium gifts, outdoor essentials and unbeatable prices to celebrate dads all summer longKATY, Texas, June 11, 2026 /PRNewswire/ -- Academy Sports +...

Purpose Receives Approval to Launch SpaceX (SPCX) Yield Shares ETF, Set to Launch on Monday, June 15, 2026

- Purpose Investments has filed, and been receipted for, an amendment to the Purpose Yield Shares prospectus qualifying Purpose SpaceX Yield Shares ETF.

Let an AI Robot Take a Part-Time Job for You: CamdClaw Opens a New Way to Explore Automated Side Income

CamdClaw, an AI-assisted quantitative trading platform, is introducing a different idea: instead of spending more hours working yourself, users can explore market opportunities with the help of an automated AI trading assistant. 
CamdClaw, an AI-assisted quantitative trading platform, is introducing a different idea: instead of spending more hours working yourself, users can explore market opportunities with the help of an automated AI trading assistant.

Novo Nordisk: Wegovy® pill (semaglutide tablets) becomes first daily GLP-1 weight-loss pill approved in the UK

Novo Nordisk's Wegovy® pill has been approved in the UK as an adjunct to a reduced-calorie diet and increased physical activity for adults

Hisense Partners with FIFA for First-Ever Sensory-Inclusive FIFA World Cup™

Consumer electronics and home appliance leader sponsors sensory inclusion initiative across all 16 host cities, helping fans with sensory sensitivities experience football's biggest stageDUBAI,...

Rent-to-Own Industry Generated $11.8 Billion in 2025 as 6.7 Million U.S. Households Seek Alternatives to Traditional Financing

2026 Industry Health Survey Highlights Strong Consumer Demand, Significant Economic Impact, and Industry InnovationAUSTIN, Texas, June 11, 2026 /PRNewswire/ -- The rent-to-own (RTO) industry...

AVAV Shareholder Alert: AeroVironment, Inc. Securities Class Action Lawsuit – Investors Should Contact SueWallSt

Alert: Claims Focus on AeroVironment's Reliance on a Single-Vendor Bespoke Contract That Allegedly Left Investors Exposed When the Space Force Shifted to Multi-Vendor Commercial...

Electric For All Answers Top Electric Vehicle Questions About Charging, Savings and Buying an EV

ElectricForAll.org analyzed and answered the most common electric vehicle (EV) questions from drivers looking to make the switch in 2026.

Zomee Announces Its Biggest Promotion for Amazon Prime Day With 35% Off Best-Selling Breast Pumps and Mom Essentials

Zomee Announces Its Biggest Promotion for Amazon Prime Day With 35% Off Best-Selling Breast Pumps and Mom Essentials

Wave Neuroscience Announces FDA Clearance of MeRT® for PTSD

FIRST-EVER FDA-CLEARED PERSONALIZED CLINICAL TREATMENT SYSTEM FOR POST-TRAUMATIC STRESS DISORDER (PTSD) ESTABLISHES A NEW CATEGORY IN PRECISION MENTAL HEALTHCARENEWPORT BEACH, Calif., June 11, 2026...

Regulatory release no. 6 – 2026: New long-term share-based incentive programme

New long-term share-based incentive programme

Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026

ZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced an upcoming presentation at Clinical Trials at the Summit 2026, taking place on June 12-13, 2026, in Las Vegas, Nevada.

Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026

ZUG, Switzerland, June 11, 2026 – Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced an upcoming presentation at Clinical Trials at the Summit 2026, taking place on June 12-13, 2026, in Las Vegas, Nevada.

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven...

Patients in the IMAAVY 30 mg/kg treatment groupa achieved statistically significant durable hemoglobin responseb, with mean hemoglobin improvement of at least 1 g/dL as...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsOptions

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers